Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 5/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 7/20 | 0.42 |
| ▸ | MEN1 | O00255 | 5/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 6/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.40 |
| ▸ | RECQL | P46063 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 3/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL950272 | 1.00 | CYP2C19 (0.45) | CYP2C19CYP1A2CYP2C9HPGDMEN1 | |
| SCHEMBL5962069 | 0.92 | CYP2C19 (0.41) | CYP2C19CYP1A2CYP2C9HPGDMEN1 | |
| SCHEMBL13735641 | 0.90 | CYP1A2 (0.43) | CYP2C19CYP1A2CYP2C9HPGDMEN1 | |
| SCHEMBL13735642 | 0.90 | CYP1A2 (0.43) | CYP2C19CYP1A2CYP2C9HPGDMEN1 | |
| SCHEMBL25623926 | 0.82 | CYP2C19 (0.41) | CYP2C19CYP1A2CYP2C9HPGDMEN1 | |
| SCHEMBL16187811 | 0.80 | CYP2C19 (0.51) | CYP2C19CYP1A2CYP2C9HPGDMEN1 | |
| SCHEMBL314333 | 0.73 | CYP1A2 (0.44) | CYP2C19CYP1A2CYP2C9HPGDMEN1 | |
| SCHEMBL4264708 | 0.73 | KEAP1 (0.33) | — | |
| SCHEMBL16865867 | 0.73 | KEAP1 (0.33) | — | |
| SCHEMBL314334 | 0.73 | CYP1A2 (0.44) | CYP2C19CYP1A2CYP2C9HPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 378 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001846-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | SERVIER LAB (FR) | 2026-01-01 | — | — | US | disclosed |
| US-20250382304-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | NUVALENT INC (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250313572-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2025-10-09 | — | — | US | disclosed |
| WO-2025106634-A1 | MCL-1 INHIBITOR COMPOUNDS AND USE IN ANTIBODY DRUG CONJUGATES | GENENTECH, INC. (US) | 2025-05-22 | — | — | WO | disclosed |
| CN-114746428-B | MCL1 inhibitor and application thereof | 加利福尼亚技术学院 | 2025-05-16 | — | — | CN | disclosed |
| US-12275742-B2 | Heteroaromatic macrocyclic ether chemotherapeutic agents | NUVALENT, INC. (US) | 2025-04-15 | — | — | US | disclosed |
| CN-119816491-A | New spirocyclohexane derivatives, pharmaceutical compositions containing them and their use as anti-apoptotic inhibitors | 法国施维雅药厂 | 2025-04-11 | — | — | CN | disclosed |
| US-20250092062-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2025-03-20 | — | — | US | disclosed |
| EP-3728256-B1 | PYRAZOLOPYRIDINE-DIAMIDES, THEIR USE AS INSECTICIDE AND PROCESSES FOR PREPARING THE SAME | PI INDUSTRIES LTD (IN) | 2024-10-02 | — | — | EP | disclosed |
| CN-118373808-A | Substituted pyrimidine or pyridine amine derivatives, compositions thereof and pharmaceutical use thereof | 上海海雁医药科技有限公司 | 2024-07-23 | — | — | CN | disclosed |
| EP-0809499-A4 | CERTAIN 1,4,5-TRI-SUBSTITUTED IMIDAZOLE COMPOUNDS USEFUL AS CYTOKINE | SMITHKLINE BEECHAM CORP (US) | 1998-10-14 | — | — | EP | disclosed |
| EP-0809499-A1 | CERTAIN 1,4,5-TRI-SUBSTITUTED IMIDAZOLE COMPOUNDS USEFUL AS CYTOKINE | SMITHKLINE BEECHAM CORPORATION (US) | 1997-12-03 | — | — | EP | disclosed |
| US-5684011-A | Pyrimidine derivatives useful as nematicides | ZENECA LIMITED (GB) | 1997-11-04 | — | — | US | disclosed |
| US-5670527-A | CYTOKINE INHIBITORS USEFUL IN TREATING ASTHMA, OSTEOPOROSIS, ARTHRITIS, INFLAMMATION, SEPSIS, CARDIOVASCULAR DISORDERS, DIABETES, MULTIPLE SCLEROSIS, SKIN DISORDERS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-09-23 | — | — | US | disclosed |
| US-5663334-A | CYTOKINE INHIBITORS FORMED BY REACTION OF IMINE WITH SULFUR SUBSTITUTED NITRILE | SMITHKLINE BEECHAM CORPORATION (US) | 1997-09-02 | — | — | US | disclosed |
| EP-0660827-B1 | HETEROCYCLIC COMPOUNDS WITH PARASITICAL ACTIVITY | ZENECA LTD (GB) | 1997-04-16 | — | — | EP | disclosed |
| US-5593992-A | CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-01-14 | — | — | US | disclosed |
| US-5593991-A | ANTIINFLAMMATORY, CYTOKINE INHIBITOR, CYCLOOXYGENASE INHIBITOR | SMITHKLINE BEECHAM CORPORATION | 1997-01-14 | — | — | US | disclosed |
| WO-1996021452-A1 | CERTAIN 1,4,5-TRI-SUBSTITUTED IMIDAZOLE COMPOUNDS USEFUL AS CYTOKINE | SMITHKLINE BEECHAM CORPORATION (US) | 1996-07-18 | — | — | WO | disclosed |
| WO-1994006777-A1 | HETEROCYCLIC COMPOUNDS WIHT PARASITICAL ACTIVITY | ZENECA LIMITED (GB) | 1994-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001846-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | BCL2, BCL2A1, BAX | CYP2C19 3314/4885CYP1A2 2158/4885CYP2C9 2339/4885 |
| US-20250092062-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | CYP2C19 3160/4885CYP1A2 2446/4885CYP2C9 2500/4885 |
| US-12275742-B2 | Heteroaromatic macrocyclic ether chemotherapeutic agents | CYP2C8, ABCB1, PAICS | CYP2C19 63/4885CYP1A2 129/4885CYP2C9 32/4885 |
| US-20250382304-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | CYP2C8, ABCB1, PAICS | CYP2C19 63/4885CYP1A2 129/4885CYP2C9 32/4885 |
| US-20250313572-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | CYP2C19 3160/4885CYP1A2 2446/4885CYP2C9 2500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.